Bevacizumab and recurrent malignant gliomas: a European perspective.
| Data(s) |
2010
|
|---|---|
| Identificador |
http://serval.unil.ch/?id=serval:BIB_9F8844432D04 isbn:1527-7755[electronic], 0732-183X[linking] pmid:20159801 doi:10.1200/JCO.2009.26.9027 isiid:000276764000028 |
| Idioma(s) |
en |
| Fonte |
Journal of Clinical Oncology, vol. 28, no. 12, pp. 188-189 |
| Palavras-Chave | #Angiogenesis Inhibitors/administration & dosage; Angiogenesis Inhibitors/therapeutic use; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal/adverse effects; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Brain Neoplasms/drug therapy; Brain Neoplasms/pathology; Clinical Trials as Topic; Europe; Evidence-Based Medicine; Glioblastoma/drug therapy; Glioblastoma/pathology; Humans; Neoplasm Recurrence, Local; Research Design; Treatment Outcome |
| Tipo |
info:eu-repo/semantics/article article |
